Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Markus Joerger(Kantonsspital St. Gallen), Jan H.M. Schellens(Utrecht University), Alwin D. R. Huitema(The Netherlands Cancer Institute), Annemieke Cats(Oncode Institute), Didier Meulendijks(AstraZeneca (Brazil)), Hilde Rosing(The Netherlands Cancer Institute), Thomas Cerny(University Hospital Bonn), Liia D. Vainchtein(The Netherlands Cancer Institute), Irma Meijerman(Utrecht University), Paul H.M. Smits(Slotervaartziekenhuis), Henk Boot(The Netherlands Cancer Institute), M. Zueger(University of St. Gallen), Jos H. Beijnen(The Netherlands Cancer Institute), Valerie D. Doodeman(Slotervaartziekenhuis)
Cited by 55
Related Papers
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451